VolitionRX (NYSEAMERICAN:VNRX) Earns “Buy” Rating from D. Boral Capital

VolitionRX (NYSEAMERICAN:VNRX)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They currently have a $3.00 price objective on the medical research company’s stock.

Separately, Maxim Group cut shares of VolitionRX from a “buy” rating to a “hold” rating in a report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $2.50.

VolitionRX Stock Performance

VNRX stock opened at $0.20 on Thursday. VolitionRX has a fifty-two week low of $0.17 and a fifty-two week high of $0.94. The company’s 50 day moving average price is $0.23 and its 200 day moving average price is $0.35. The firm has a market capitalization of $26.65 million, a price-to-earnings ratio of -0.85 and a beta of 1.33.

Hedge Funds Weigh In On VolitionRX

Several institutional investors and hedge funds have recently added to or reduced their stakes in VNRX. Armistice Capital LLC raised its stake in shares of VolitionRX by 10.4% during the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after buying an additional 887,351 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after buying an additional 85,816 shares in the last quarter. Citadel Advisors LLC grew its holdings in VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after acquiring an additional 135,775 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new position in VolitionRX during the second quarter worth $52,000. Finally, Squarepoint Ops LLC purchased a new position in VolitionRX in the fourth quarter worth $34,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.